Histone deacetylase 1 and 2 in mesenchymal tumors (Q82255556)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Histone deacetylase 1 and 2 in mesenchymal tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Marina Pacheco

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Torsten O Nielsen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

28 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

222-230

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22037263%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.157

15 January 2020

exact match

0 references

cites work

The molecular signature of oncofusion proteins in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

The polycomb group protein EZH2 is involved in progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Nuclear beta-catenin in mesenchymal tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

HDAC family: What are the cancer relevant targets?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

HDAC expression and clinical prognosis in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

The significance of strong histone deacetylase 1 expression in the progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

Histone deacetylase inhibitors as anti-neoplastic agents.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.157

7 January 2021